1849590-02-8|Tomivosertib HCl|6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride|-范德生物科技公司

Tomivosertib HCl

NMR下载 COA and HPLC MSDS下载
names：
6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride
CAS号：
1849590-02-8
MDL Number：
MF(分子式)： C17H21ClN6O2 MW(分子量)： 376.845
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride
英文别名	Tomivosertib HCl; hydrochloride; Tomivosertib HCl; eFT508; eFT-508; eFT 508; eFT508 hydrochloride
CAS号	1849590-02-8
SMILES	O=C(C1=C(C)C=C(NC2=NC=NC(N)=C2)C(N13)=O)NC43CCCCC4.[H]Cl
Inchi	InChI=1S/C17H20N6O2.ClH/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17;/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21);1H
InchiKey	WBGPPUUXCGKTSC-UHFFFAOYSA-N
分子式 Formula	C17H21ClN6O2
分子量 Molecular Weight	376.845
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tomivosertib HCl(CAS:1849590-02-8 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Megat S, Ray PR, Moy JK, Lou TF, Barragan-Iglesias P, Li Y, Pradhan G,Wanghzou A, Ahmad A, Burton MD, North RY, Dougherty PM, Khoutorsky A, SonenbergN, Webster KR, Dussor G, Campbell ZT, Price TJ. Nociceptor translationalprofiling reveals the Ragulator-Rag GTPase complex as a critical generator ofneuropathic pain. J Neurosci. 2018 Nov 20. pii: 2661-18. doi:10.1523/JNEUROSCI.2661-18.2018. [Epub ahead of print] PubMed PMID: 30459229.

[2]Reich SH, Sprengeler PA, Chiang GG, Appleman JR, Chen J, Clarine J, Eam B,Ernst JT, Han Q, Goel VK, Han EZR, Huang V, Hung INJ, Jemison A, Jessen KA,Molter J, Murphy D, Neal M, Parker GS, Shaghafi M, Sperry S, Staunton J, StumpfCR, Thompson PA, Tran C, Webber SE, Wegerski CJ, Zheng H, Webster KR.Structure-based Design of Pyridone-Aminal eFT508 Targeting DysregulatedTranslation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1and 2 (MNK1/2) Inhibition. J Med Chem. 2018 Apr 26;61(8):3516-3540. doi:10.1021/acs.jmedchem.7b01795. Epub 2018 Mar 29. PubMed PMID: 29526098.

[3] Dreas A, Mikulski M, Milik M, Fabritius CH, Brzózka K, Rzymski T.Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 andMNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNKInhibitors. Curr Med Chem. 2017;24(28):3025-3053. doi:10.2174/0929867324666170203123427. Review. PubMed PMID: 28164761.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开